Compound targets hot flashes in women receiving breast cancer therapy
ATLANTA--(BUSINESS WIRE)--A Phase I clinical study has found positive results with a compound aimed at treating hot flashes in women receiving anti-estrogen therapy for breast cancer. Q-122, developed for the treatment of vasomotor symptoms in women treated with hormone-blocking therapy, is the lead compound of QUE Oncology, Inc., a biotechnology company formed by Emory University and The University of Queensland’s commercialization company UniQuest in Brisbane, Australia.
“A Single Center, Two Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effect on Vasomotor Symptoms of Q-122 in Female Subjects with Breast Cancer and Receiving an Aromatase Inhibitor or Tamoxifen”
Women taking estrogen-blocking drugs have few options to treat the debilitating hot flashes that often occur as a result of their treatment. Hot flashes were reduced by nearly 60 percent among study participants. A number of subjects experienced a complete response, having their hot flashes decrease from more than 50 per week to zero.
Study Q-1001 was “A Single Center, Two Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effect on Vasomotor Symptoms of Q-122 in Female Subjects with Breast Cancer and Receiving an Aromatase Inhibitor or Tamoxifen”. Sixteen subjects received oral doses of Q-122 of 100 mg daily or 200 mg daily for 28 days.
“These study results are exciting, especially with a non-hormonal drug candidate, and they position us well to move into a dose-defining Phase 2 study in this patient population,” says Wendy Painter, MD, MPH, chief executive officer of QUE Oncology.
QUE Oncology is focused on preventing and treating life-threatening cancers and related conditions with therapies that have fewer side effects, thereby improving quality of life while providing a greater chance of recovery. QUE Oncology has well-developed research assets with a rich pre-clinical pipeline of cancer therapeutics.
QUE Oncology Dr. Painter, 919-619-1653 http://QUEOncology.com